MICHELE DE TURSI

ASSOCIATE PROFESSOR

University "G. d'Annunzio"

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Michele De Tursi is an Associate Professor at the University G. D'Annunzio, Italy. His research focuses on the clinical outcomes of various cancers, particularly metastatic colorectal cancer and non-small cell lung cancer, emphasizing the role of biomarkers and treatment strategies. Recent publications include studies on the prognostic significance of extracellular vesicles and the implications of immune-related adverse events in cancer therapy.

Articles (11)

Year:

2025

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (7)

Simone De Fabritiis

University of Chieti-Pescara

ITALY

View details

Laura De Lellis

ITALY

View details

Fabio Gelsomino

ITALY

View details

Nicola Tinari

University of Chieti-Pescara

ITALY

View details

Nicola De'Angelis

FRANCE

View details

Manuela Iezzi

Associate Professor

University of Chieti-Pescara

ITALY

View details

olga nigro

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

MICHELE DE TURSI

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Low Phosphatidylserine+ Cells Within the CD34+/CD45dim/CD117(c-kit)+ Subpopulation Are Associated with Poor Outcomes in Metastatic Colorectal Cancer

Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study

High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer

Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer

Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study

Speed rate (SR) as a new dynamic index of melanoma behavior

Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

P-257 Deep polychromatic flow cytometry characterization of circulating endothelial cells in metastatic colorectal cancer patients

Collaborators (7)

Simone De Fabritiis

Laura De Lellis

Fabio Gelsomino

Nicola Tinari

Nicola De'Angelis

Manuela Iezzi

olga nigro

Make your next move.